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Abstract
The novel coronavirus (CoV), CoV disease (COVID)-19, and the ongoing pandemic, is changing every aspect of 
the human life. Furthermore, the COVID-19 pandemic has a profound impact on health-care worldwide, with no 
exception in dermatology care units. At the time of pandemic, constant fear and stress are present on the surface. 
Skin diseases are the most common somatic causes of psychological disorders and, conversely. During a stressful 
situation, the body has power to adjust and to maintain its well-being, but with prolonged exposure to stress, the first 
negative changes such as fear, anxiety, and depression will eventually lead to chronic fatigue and an increased risk of 
disease. The proportion of patients reporting emotional triggers varies with the disease, ranging from approximately 
50% in acne to 90% in rosacea, alopecia areata, psoriasis, neurotic excoriations, and lichen simplex and may be 
100% for patients with hyperhidrosis. In this paper, we will look at the most common psychodermatological disorders 
and its implication in the era of COVID-19 pandemic. According to all the pathophysiological conditions that indicate 
the association of skin diseases with stress, it is normal to expect their deterioration and occurrence in this pandemic 
period. We will be witnessing a growing number in patients’ consultations with chronic urticaria, dermographism, 
worsening rosacea, generalization, and relapses of psoriasis. It is needed to be prepared for as many cases as 
possible, because the psychological consequences will still be felt. We encourage more comprehensive studies of 
the implications of the COVID-19 pandemic in these patients.
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Introduction
The coronavirus (CoV) disease (COVID)-19 
pandemic, or COVID-2019, is caused by several acute 
respiratory syndrome CoV-2. On January 12, 2020, 
the World Health Organization (WHO) confirmed that 
a novel CoV was the cause of a respiratory illness 
in a cluster of people in Wuhan City, Hubei Province 
China. The WHO declared the outbreak a public health 
emergency of international concern on January 30, and 
a pandemic on March 11. On the end of May almost 
6 million cases of COVID-19 have been reported in 
more than 230 countries, resulting in more than 370,000 
deaths.
The novel CoV, COVID-19, and ongoing 
pandemic, is changing every aspect of human life. 
Furthermore, COVID-19 pandemic has a profound 
impact on health-care worldwide, with no exception in 
dermatology care units. The dermatological practices are 
affected, although with much OR less extensity than the 
emergency and intensive care departments which are 
working with the suspected and confirmed COVID-19 
patients. Chen et al. reported the impact on dermatology 
outpatient care at the outbreak epicenter in Wuhan, 
China [1]. To meet the medical requirements and reduce 
the flow of patients to the dermatology departments, the 
measures which were taken by the public hospitals and 
private practices are dramatically reduction in outpatient 
consultations. In order to care for the patients safely 
and effectively, dermatological practices converted 
the face-to-face examination to telephone and online 
consultations. Esthetic dermatological procedures, laser 
sessions, have been stopped, almost completely. Only 
patients with dermatologic emergencies and acute skin 
failures are admitted in hospitals. In an era of quarantine 
and isolation, dermatologists utilize teledermatology 
better than other specialties. Communication modes 
can be video, audio, and text based – Viber, WhatsApp, 
and Facebook messenger, are the virtual tools being 
used for teledermatology practices. The advantages 
using teledermatology are: Permits consultation without 
increased risk of infection, very important is cost-effective, 
and provides accurate diagnostic information [2]. The 
key aspect of risk management in the dermatology 
practices is prevention of COVID-19 in population at 
risk, and that is the patient with chronic inflammatory 
skin disease, patients on immunosuppressive, and 
biologics therapy. British Association of Dermatologists 
(BAD) provided guidelines for high risk patients 
on immunosuppressive medications or biologics/
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Monoclonal (anti-tumor necrosis factor drugs, Interleukin 
(IL) 17 agents, anti-B cell, IL-6 agents, and IL-1) or 
novel molecule immunosuppressant (apremilast, JAK 
inhibitors) and patients on corticosteroid dose of ≥20 
mg of prednisolone/daily for more than 4 weeks; to 
undergo with self-isolation up to 12 weeks. Patients 
treated with single immunosuppressant or biologics and 
no comorbidities, stressed the need to maintain social 
distancing [3]. BAD advises using teledermatology and 
avoiding hospital visits as much as possible [4]. American 
Academy of Dermatology and international Psoriasis 
council also suggest recommendations on using the 
biologics and immunosuppressant in COVID-19 positive 
patients [5], [6]. Guidelines for dermatoscopy during 
COVID-19 pandemic have been also suggested [7].
COVID-19 Pandemic and 
Psychodermatological Disorders. What to 
Expect?
At the time of COVID-19 pandemic, constant 
fear and stress are present on the surface. During a 
pandemic and restricted movement, the constant need 
to wear face masks, adhere to the rules of keeping 
a social distance of 2 m, constantly washing hands, 
and continuously media accentuating about the 
danger of the virus and infection led to milder or more 
severe mental problems. Skin diseases are the most 
common somatic causes of psychological disorders 
and, conversely. During a stressful situation, the body 
has the power to adjust to maintain its well-being, but 
with prolonged exposure to stress, the first negative 
changes such as fear, anxiety, and depression will 
eventually lead to chronic fatigue and an increased 
risk of disease. In this paper, we will look at the most 
common psychodermatological disorders and its 
implication in the era of COVID-19 pandemic.
Dermatological conditions are closely related 
to stress. Stress is a trigger factor for a lot of cutaneous 
diseases: Alopecia areata, psoriasis, vitiligo, lichen 
planus, acne, atopic dermatitis, and urticaria. What 
matter is the “perceived stress,” or patient’s perception 
of the stressful situation, which sometimes its greater 
than the stress itself. This perception is usually 
influenced by the psychological state of the patient. 
Anxiety, depression could change the perception of the 
event [8].
The exact prevalence of psychological factors 
that affect skin disease is not known; however, it has 
been estimated to be 25–33% in various studies [8]. 
Brain, nerves, and skin are embryologically derived 
from the neural plate in the ectoderm. The neuro-
immuno-cutaneous-endocrine model was proposed by 
O’Sullivan et al., to explain the relationship of the body 
and mind [9].
The role of the neuropeptides, hormones, and 
neurotransmitters in the pathogenesis of psychotic 
diseases is subject of research by a number of 
scientists. Stress is known to activate the two major 
neural pathways, the first is the hypothalamic-pituitary-
adrenal axis and the second is the sympathetic nervous 
system. Stress triggers the secretion of adrenal 
glucocorticosteroids and catecholamines, the secreted 
amount of which, will act as a negative feedback on 
the secretion of corticotropin-releasing hormone, which 
stimulates the sympathetic nervous system and the 
secretion of epinephrine and norepinephrine [8].
Catecholamines and corticosteroids have an 
inhibitory effect on the immune system, reduce the 
secretion of IL-2 and IL-8, affect the differentiation 
of T cells, and activate cellular immunity. From the 
terminal nerve endings in the skin begin to release 
neuropeptides such as calcitonin gene released peptide 
and substance P, which are the main culprits for the 
existence of psychosomatic skin diseases. As a result 
of these reactions, the body’s allergic and inflammatory 
responses increase [8]. Psychological stress has a 
negative influence on barrier function of the skin and 
its antimicrobial defense, both by glucocorticoid-
dependent mechanism [10].
Although there is no single universally accepted 
classification system of psychocutaneous disorders 
and many of the conditions are overlapped into different 
categories, the most widely accepted system is that 
devised by Koo and Lee [11]. In psychophysiological 
psychocutaneous disorders, the skin disease is not 
caused by stress but appears to be precipitated or 
exacerbated by the stress [11]. The proportion of 
patients reporting emotional triggers varies with the 
disease, ranging from approximately 50% in acne to 
90% in rosacea, alopecia areata, neurotic excoriations, 
and lichen simplex and may be 100% for patients with 
hyperhidrosis [11]. Onset or exacerbation of psoriasis 
can be triggers by a number of common stressors. 
Stress has been reported in 44% of patients before the 
initial flare of psoriasis, and recurrent flares have been 
attributed to stress in up to 80% of individuals [12]. In 
a study analyzing, the stressful situations described 
in psoriatic patients the most common were death of 
a family member, own disease or serious disease of 
a family member [13]. Stressful life events precede 
the onset of disease in more than 70% of atopic 
dermatitis patients [14]. A case–control study of 
Willemsen et al. reported higher score and impact of 
lifetime and childhood traumatic events, in alopecia 
areata adults [15]. There are reports that alopecia 
areata pediatric patients experienced more stressful 
events [16]. Stressful events precede the onset of 
lesions in vitiligo patients, compared to controls [17]. 
Severe emotional stress may exacerbate pre-existing 
urticaria. Increased emotional tension, fatigue, and 
stressful life situations may be primary factors in more 
than 20% of cases and are contributory in 68% of these 
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patients [11]. There is increasing evidence that stress 
has a role in recurrent herpetic infection [18]. Several 
psychological stress of any sort, may depress cell-
mediated immune response, predisposing children to 
the Herpes zoster virus [19].
Such evidence raises the possibility that the 
psychosocial stress induced by the COVID-19 pandemic 
can potentially lead to exacerbations or onset of common 
inflammatory skin conditions (e.g., psoriasis, atopic 
eczema, urticaria, and pruritic conditions), both in the 
short term and after the resolution of the pandemic [20]. 
Soon, we will have to deal with short- and long-term 
psychosocial effects related to the COVID-19 pandemic 
on patients with dermatological disorders, and we 
encourage comprehensive studies of the implications 
of the COVID-19 pandemic in these patients.
Conclusion
As COVID-19 pandemic rapidly spreads across 
the world, it is inducing a considerable degree of fear, 
worry and stress, for many individuals, arising from the 
disease itself, and from measures such as social and 
physical distancing. In public mental health terms, the 
main psychological impact to date is elevated rates 
of stress or anxiety. However, as new measures and 
impacts are introduced, especially quarantine and its 
effects on many people’s usual activities, routines or 
livelihoods – levels of loneliness, depression, using 
drugs, alcohol, and self-harm or suicidal behavior are 
also expected to rise.
Stressful events could induce a psychosomatic 
disease, especially in some patients with high 
reactivity to stress. We will be witnessing a growing 
number in patient consultations with chronic urticaria, 
dermographism, worsening rosacea, seborrheic 
dermatitis, generalization, and relapses of psoriasis 
and alopecia. Mental stress can influence the disease, 
causing flare-ups and being the main triggering 
factor. Stress suggests a poor prognosis. In general, 
there is a need for improved coordination of primary 
healthcare, dermatovenereologists and psychiatric, and 
psychological services in the health system. It is needed 
to be prepared for as many cases as possible, because 
the psychological consequences will still be felt.
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